$
20.330
-0.53(-2.541%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
20.960
Open
20.960
VWAP
20.45
Vol
38.03K
Mkt Cap
219.72M
Low
20.250
Amount
777.61K
EV/EBITDA(TTM)
--
Total Shares
9.28M
EV
187.88M
EV/OCF(TTM)
--
P/S(TTM)
10.95
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
5.68M
+12.12%
-0.568
-16.47%
6.66M
+52.97%
-0.638
-34.9%
7.61M
+30.31%
-0.704
+95.56%
Estimates Revision
The market is revising Downward the revenue expectations for MediWound Ltd. (MDWD) for FY2025, with the revenue forecasts being adjusted by -0.21% over the past three months. During the same period, the stock price has changed by 11.15%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.21%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-31.9%
In Past 3 Month
Stock Price
Go Up
up Image
+11.15%
In Past 3 Month
6 Analyst Rating
up Image
42.65% Upside
Wall Street analysts forecast MDWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDWD is 29.00 USD with a low forecast of 25.00 USD and a high forecast of 34.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
up Image
42.65% Upside
Current: 20.330
sliders
Low
25.00
Averages
29.00
High
34.00
Oppenheimer
Oppenheimer
Outperform
to
Outperform
downgrade
$36 -> $34
2025-06-02
Reason
Oppenheimer assumed coverage of MediWound with an Outperform rating with a price target of $34, down from $36. The firm notes the company's Q1 update highlighted progress across its clinical and commercial programs. Global EscharEx Phase 3 VALUE trial recruitment is underway, with most U.S. sites open, and interim data expected mid-2026. Given design similarities to Phase 2, Oppenheimer views Phase 3 as significantly derisked. MediWound's strategic collaborations and overall key opinion leader enthusiasm further validate EscharEx's clinical/commercial potential, the firm adds.
H.C. Wainwright
Swayampakula Ramakanth
Buy
upgrade
$25 -> $31
2025-05-22
Reason
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on MediWound to $31 from $25 and keeps a Buy rating on the shares following the Q1 report.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$25
2025-03-20
Reason
Craig-Hallum
Chase Knickerbocker
Strong Buy
Initiates
$39
2025-02-28
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$25
2025-01-10
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$28 → $25
2024-11-27
Reason

Valuation Metrics

The current forward P/E ratio for Mediwound Ltd (MDWD.O) is -8.58, compared to its 5-year average forward P/E of -9.38. For a more detailed relative valuation and DCF analysis to assess Mediwound Ltd 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-9.38
Current PE
-8.58
Overvalued PE
-3.68
Undervalued PE
-15.08

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.70
Current EV/EBITDA
-7.45
Overvalued EV/EBITDA
2.08
Undervalued EV/EBITDA
-11.47

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
4.97
Current PS
8.63
Overvalued PS
6.85
Undervalued PS
3.10

Financials

Annual
Quarterly
FY2025Q1
YoY :
-20.33%
3.96M
Total Revenue
FY2025Q1
YoY :
+39.93%
-5.23M
Operating Profit
FY2025Q1
YoY :
-92.54%
-726.00K
Net Income after Tax
FY2025Q1
YoY :
-93.33%
-0.07
EPS - Diluted
FY2025Q1
YoY :
-8.72%
-4.80M
Free Cash Flow
FY2025Q1
YoY :
+52.58%
18.66
Gross Profit Margin - %
FY2025Q1
YoY :
-90.63%
-18.36
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

MDWD News & Events

Events Timeline

2025-05-21 (ET)
2025-05-21
07:03:42
MediWound reports Q1 EPS (7c), consensus (66c)
select
2025-05-13 (ET)
2025-05-13
07:45:15
MediWound announces publication of Phase II EscharEx data
select
2025-03-19 (ET)
2025-03-19
16:08:35
MediWound files to sell 1.26M ordinary shares for holders
select
Sign Up For More Events

News

4.0
05-22Benzinga
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday
3.0
05-21NASDAQ.COM
MediWound (MDWD) Q1 2025 Earnings Call Transcript
9.5
05-21Newsfilter
MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update
Sign Up For More News

FAQ

arrow icon

What is Mediwound Ltd (MDWD) stock price today?

The current price of MDWD is 20.33 USD — it has decreased -2.54 % in the last trading day.

arrow icon

What is Mediwound Ltd (MDWD)'s business?

arrow icon

What is the price predicton of MDWD Stock?

arrow icon

What is Mediwound Ltd (MDWD)'s revenue for the last quarter?

arrow icon

What is Mediwound Ltd (MDWD)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Mediwound Ltd (MDWD)'s fundamentals?

arrow icon

How many employees does Mediwound Ltd (MDWD). have?

arrow icon

What is Mediwound Ltd (MDWD) market cap?